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Introduction
Methods. Urapidil is a post-synaptic a 1 adrenoceptor antagonist, which is widely used to control hypertensive Hypertensive disorders are the most common medical crises unrelated to pregnancy. Since it is known that complication of pregnancy, and are an important cause pre-eclampsia is associated with increased sympathetic of maternal and perinatal morbidity and mortality activity, administration of an a 1 adrenoceptor antagonworldwide. Pre-eclampsia has traditionally been ist provides a reasonable therapeutic basis. So far there described as the occurrence of hypertension, oedema, is only one report describing the i.v. use of urapidil in and proteinuria after 20 weeks' gestation in a previthe treatment of hypertension in pregnancy unresponsously normotensive woman. The aetiology of preive to dihydralazine and one report which describes eclampsia is not well understood, but a recently pubthe oral use of urapidil. In an earlier pilot study we lished paper indicates a marked increase in sympathetic examined the dose range for i.v. application of urapidil activity resulting in a high peripheral vascular resistnecessary for adequate blood pressure control in ance, which in turn causes a rise in blood pressure [1] . patients with pre-eclampsia. In the present randomized Antihypertensive treatment is mandatory in order to controlled study 26 white women with pre-eclampsia reduce morbidity and mortality in both the mother and hypertension in pregnancy were included. and the fetus or neonate. Treatment was not blinded. During the initial period
The primary objective of treatment in women with of intensive intravenous treatment all subjects were severe hypertension and pre-eclampsia is to prevent under constant surveillance by a physician and a nurse.
complications such as encephalopathy and haemorResults. Effective prolonged control of blood pressure rhage. However, antihypertensive drugs have potential (values below 150/100 mmHg) was achieved in all adverse effects on the mother and the fetus or neonate. patients of the two groups. In one patient of the Therefore some of the most beneficial antihypertensive dihydralazine group signs of lightheadedness and near drugs cannot be used in pregnancy, either because they syncope were noted. After this side-effect of dihydralazare contraindicated, such as ACE inhibitors, or because ine the patient was treated with urapidil. At the end their adverse effects are increased when administered in combination with magnesium sulphate, such as no more available in all countries. In addition there for adequate blood pressure control in patients with pre-eclampsia [10, 11] . As the preliminary data proare also reports of adverse maternal effects of labetalol like scalp tingling, tremulousness, postural hypoten-vided sufficient evidence for the efficacy and safety of urapidil, the aim of our present study was to perform sion, and headache [3] . Some authors showed sideeffects of beta-blockers used in the treatment of hyper-a prospective randomized comparison of dihydralazine and urapidil used for treatment of hypertension in tension in pregnancy [4] .
Antihypertenive drugs can affect the fetus either pregnancy, in order to develop new improved treatment strategies with fewer unwanted effects than usually indirectly by lowering uteroplacental blood flow, or directly by influencing the umbilical or fetal cardiovas-precipitated with dihydralazine. cular circulation. Therefore an additional aim of treatment is to reduce fetal complications by using antihypertensive drugs without affecting fetal circula-Subjects and methods tion to a relevant extent.
In many countries dihydralazine is considered the Twenty-six white women with pre-eclampsia and hypertendrug of choice for treating hypertension in pregnancy, sion in pregnancy were included in the trial. Pre-eclampsia because it has now been used safely for about 30 years, was defined according to the criteria of the International and the introduction of a new drug in pregnancy is a Society for the Study of Hypertension in Pregnacy [13] .
These criteria include the lack of hypertension, cardiovasdifficult task with partially unknown hazards. But in cular, or renal disease before pregnancy and blood-pressure our opinion there are some pharmacodynamic values exceeding 140/90 mmHg after 20th week of gestation, properties of dihydralazine resulting in adverse effects confirmed by two consecutive readings at least six h apart, (tachycardia, headache, nausea, vomiting) which are with blood pressure reverting to normal within 2 months potentially dangerous, and therefore favour after delivery [12, 13] . Tables 1 and 2 show the demographic re-evaluation of the risk benefit ratio of this agent by data of the two patient groups. direct comparison with other antihypertensive drugs Patients who were referred to the Department of Obstetrics [5] [6] [7] . urapidil directly resulting in peripheral vasodilatation developed severe pre-eclampsia between 26 and 38 weeks of provides a rational approach for improving therapy gestation were enrolled in the study, unless they had received [1] . So far there is only one report which describes the antihypertensive drugs intravenously before admission to use of urapidil in the treatment of hypertension in our hospital. pregnancy [9] . In a previous pilot study we examined
The protocol for the use of urapidil in severe pre-eclampsia was approved by the Ethics Committee of the University of the dose range for i.v. application of urapidil necessary *Proteinuria+, 0.3-1 g/l; proteinuria++, 1-5 g/l; proteinuria +++,>5 g/l ). Heidelberg. Written informed consent was obtained from all (i.v.) hydralazine was given in the same way (perfusorapplication) according to the standard protocol used in our participants.
Data collected on every patient included the following: department until delivery. Tables 1 and 2 show the duration of treatment. age, obstetric history, blood pressure (in the supine position with a wedge device preventing complete supine position, Patients in both groups also received i.v. magnesium ascorbate ( loading dose 4 g, maintenance dose 1-2 g/h, as taken with a standard sphygmomanometer using phase 4 of the Korotkoff sounds as the diastolic pressure), heart rate, determined by patellar reflexes. Steroid treatment to accelerate lung maturation was used in patients before 34 weeks of patellar reflexes, and proteinuria. In agreement with the practical management recommendations of the ISSHP-gestation.
As long as both maternal and fetal conditions remained (International Society for the Study of Hypertension in Pregnancy) Australian section ( Eileen D. M. Gallery) and in stable, pregnancy was allowed to continue until the 36th week, when labour was induced. During this period the aim accordance with common practice in Germany we used phase 4 of the Korotkoff sounds [14] .
of the reduction of high blood pressure was a diastolic blood pressure between 90 and 95 mmHg. An initial ultrasonographic evaluation of fetal status was performed. Concurrent hypertensive treatment was stopped. No volume expanders were administered. Subjects were randomly assigned to the urapidil or dihydralazine group Results [13/13] according to a computer-generated randomization list. Treatment was not blinded.
During the initial period of intensive treatment all subjects Initially 26 subjects met the criteria for enrollment in were under constant surveillance of a physician and a nurse. the study. None of the patient dropped out during the Monitoring included measurements of blood pressure and study. There were no significant differences between heart rate every 20 min; hourly determinations of urine the groups with regard to mean age (29.08±5.06) vs output and patellar reflexes; daily blood analyses, which (31.08±3.80), mean length of gestation on admisincluded complete blood count, electrolytes, liver enzymes, sion (35.08±2.02 weeks vs 33.85±3.58 weeks).
serum proteins, and a coagulation profile; daily determination Figure 1 illustrates the time course of systolic blood of urinary volume, protein excretion; prolonged and contin-pressure in the two groups on admission in the time ous FHR monitoring. of 6 h after the beginning antihypertensive treatment.
Twenty-four hours after stabilization of blood pressure Table 3 shows the standard deviations of the systolic and thereafter until delivery, the monitoring regimen was simplified and included, measurements of blood pressure and blood pressure. There were no significant differences heart rate six times daily, twice-daily determination of in mean systolic blood pressure values on admispatellar reflexes, daily blood and urine analyses as noted sion (159.46±11.42 mmHg for urapidil vs 160.77± previously, including liver function tests; FHR monitoring 13.36 mmHg for dihydralazine). During the initial three times daily; and weekly ultrasound assessment of observation period of 6 h systolic blood pressure fell fetal growth.
21 mmHg in the urapidil group (P<0.001) and Urapidil treatment was started with a bolus dose of 6 mmHg in the dihydralazine group (P<0.002). 6 .25 mg intravenously, followed by a second slow bolus 106.54±4.74 mmHg for dihydralazine). In both groups Effective prolonged control of blood pressure (values consistently below 150/100 mmHg) was achieved in all the diastolic blood pressure was decreased below 100 mmHg. During the initial 6 h diastolic blood pres-patients of the two groups. In one patient of the dihydralazine-group signs of lightheadedness and sure fell 13 mmHg in the urapidil group (P<0.001) and 18 mmHg in the dihydralazine group (P<0.001). nearsyncope were noted. After this side-effect of dihydralazine the patient was treated with urapidil. Table 4 shows the standard deviations of the diastolic blood pressure.
The average dose of the antihypertensive drugs in For treatment and management of hypertension in pregnancy and pre-eclampsia different drugs can be Figure 3 shows the time course of heart rate in the both groups. At the end of the initial observation used. Hutton et al. showed that oral labetalol and methyldopa are the drugs most used by UK consultants period the maternal heart rate in the dihydralazine group (90±15 b.p.m.) was higher than in the urapidil [15, 16 ] . Labetalol is no more available in Germany.
Methyldopa is only used for the mild form of pregroup (78±11 b.p.m.). Table 5 shows the standard deviations of the heart rates in the two groups.
eclampsia. Atenolol can be associated with intrauterine growth retardation [17] . In the present study we The data on proteinuria are shown in Tables 1 and  2 . Because it was not possible to measure the amount focussed on the i.v. administration of antihypertensive drugs in patients with pre-eclampsia. In Germany of protein in a 24-h urine sample, we used the semiquantitive urine-stick method. In the urapidil group dihydralazine is the preferred i.v. drug. However dihydralazine is known to have some disadvantages for the two patient and in the dihydralazine group three patients had a proteinuria of more than 5 g/l.
mother and the fetus or neonate [4] [5] [6] 18, 19] . Therefore it is desirable to develop improved treatment strategies. Six patients treated with urapidil were delivered vaginally and seven by caesarean section, compared Therapeutic compounds reducing peripheral vascular resistance by a 1 adrenoceptor blockade could avoid with two vaginal deliveries and 11 caesareans in the dihydralazine group. During the initial phase of anti-maternal tachycardia, and so might be preferable to dihydralazine. Primarily drugs already established in hypertensive treatment no abnormal fetal heart-rate patterns were found. the treatment of hypertension like urapidil should be used for comparison. Literature data show that the a 1 The birth-weight in the two groups was comparable (2228±804 g in the urapidil group vs 1820±845 g in blocking drug urapidil was effective and safe as a second-line drug in patients with pre-eclampsia in the dihydralazine group). Tables 6 and 7 show the outcome of the neonates. One neonate of the dihydrala-whom dihydralazine did not lower blood pressure sufficiently [9] . Our own pilot study provided evidence zine group, weighing 460 g, died of respiratory failure and in the course of immaturity. All other neonates that urapidil probably was effective and safe also as a first-line drug [10, 11] . Therefore we performed a were discharged in healthy condition. No congenital Number  13  13  13  13  13  13  13  13  13  13  13  13  13  13  13  13  13  13  13  Mean  88  86  89  88  89  88  90  89  90  90  92  92  92  93  91  90  89  89  90  SD  14  14  17  13  13  14  14  13  13  12  12  13  15  12  16  15  13  14  15  Urapidil group   Time (min)  0  20  40  60  80 100 120 140 160 180 200 220 240 260 280 300 320 340 360  Number  13  13  13  13  13  13  13  13  13  13  13  13  13  13  13  13  13  13  13  Mean  85  83  81  83  83  83  82  81  81  82  82  81  80  79  78  77  77  78  78  SD  10  8  8  7  7  6  7  7  7  7  7  7  8  9  9  10  11  11  11 prospective direct comparison. To prevent the well-or excessive falls in blood pressure. Compared to the patients in the dihydralazine group the patients in the known statistical biases in studies establishing a cause-effect relationship, the preferable study design would urapidil group did not develop reflex tachycardia. The reflex tachycardia caused by dihydralazine also was be a randomized, controlled, and double-blind clinical trial. However, double-blind drug administration was found by other investigators [9, 19] and is a serious adverse effect for the mother. In 19/33 patients Vink not possible in our study because urapidil is an antihypertensive drug with pharmacodynamic properties et al. found pathological fetal heart rate ( FHR) patterns coinciding with a fall in blood pressure after a different from those of dihydralazine. Since hypertension in pregnancy always needs to be treated effectively, bolus-injection of 12.5.mg dihydralazine over a period of 4 min [5] . In our study we observed no pathological comparative studies can only include active treatment, dihydralazine and urapidil, but no placebo controls.
FHR-pattern at the beginning of the antihypertensive treatment, probably because blood pressure was The present study is to our knowledge the first randomized trial comparing urapidil with decreased only very slowly. The high rate of caesarean deliveries, similiar to that dihydralazine.We found that treatment with urapidil can decrease the high blood pressure in patients with reported by Constantine et al. and Fenakel et al. [18, 19] reflects our liberal indications for abdominal pre-eclampsia without serious side-effects. The haemodynamic effects of urapidil were more predictable than delivery and was not related to treatment.
There was no fetal death or fetal disease caused by those of dihydralazine. Urapidil did not cause sudden the drugs used in this study. One neonate of the group 14 days. So the duration of treatment was short as compared to the Oxford study. Nevertheless we will dihydralazine group died in the course of prematurity. J. Cockburn and co-workers 1982 reported about the examine all the children of treated women after 4 and 7 years, at a time when the Oxford study showed effects of specific treatment on the development of the children of patients with hypertension in pregnancy significant differences in the height and weight of boys.
At the moment there is no known difference in growth [20] . At the age of 4 years there were no differences in height, weight, health, and the frequency of sight and or development of the children of the mothers treated with dihydralzine or urapidil. hearing problems, but sons of treated women had significantly smaller heads. Our study was performed Altogether we conclude that urapidil was responsible for the improved maternal and fetal outcomes. This is between 1994 and 1997, so we cannot actually compare our data with the report of the Oxford group, because supported by the following findings: the two treatment groups were similiar with respect to all known factors the oldest children are younger than 4 years. But we do know that none of the children has neurological that might have influenced the outcome in severe preeclampsia. The efficacy and adverse effects of dihydefects since otherwise the children would be registered in our Department of Pediatrics. In the Oxford study dralazine in the present study are in agreement with earlier results reported by other authors [5, 9, 19] . the mean time of entry was less than 20 weeks' gestional age whereas in our study it was 34-35 weeks. Therefore The reduction of intracerebral pressure reported by Knichwitz could be an additional advantage of urapidil in our study the maximum duration of treatment in the diydralazine group only was 19 and in the urapidil in the treatment of patients with pre-eclampsia [21] .
